Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Riedl

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Journal of Neuroimmunology|September 1, 1989
Neuroendocrine regulation of in vivo cytokine production and effects: I. In vivo regulatory networks involving the neuroendocrine system, interleukin-1 and tumor necrosis factor-alphaL D Butler, N K Layman, P E Riedl, et al.
American Journal of Veterinary Research|May 26, 2017
Evaluation of the effects of a 4.7-mg deslorelin acetate implant on egg laying in cockatiels (Nymphicus hollandicus)Noémie M Summa, David Sanchez-Migallon Guzman, Emma L Wils-Plotz, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 11, 2020
Ixekizumab improves secondary lesional signs, pain and sexual health in patients with moderate-to-severe genital psoriasisJ F Merola, P-D Ghislain, J N Dauendorffer, et al.
Immunopharmacology and Immunotoxicology|January 1, 1989
Interleukin-2 induced systemic toxicity: induction of mediators and immunopharmacologic interventionL D Butler, K M Mohler, N K Layman, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 1, 2022
An integrated analysis of herpes virus infections from eight randomized clinical studies of baricitinib in adults with moderate-to-severe atopic dermatitisT Werfel, A D Irvine, C Bangert, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 6, 2023
Speed of clinical improvement in the real-world setting from patient-reported Psoriasis Symptoms and Signs Diary: Secondary outcomes from the Psoriasis Study of Health Outcomes through 12 weeksA Reich, A Pinter, J-T Maul, et al.
The Journal of Dermatological Treatment|September 22, 2021
Pregnancy outcomes in patients with psoriasis, psoriatic arthritis, or axial spondyloarthritis receiving ixekizumabA Egeberg, L Iversen, A B Kimball, et al.
The British Journal of Dermatology|November 17, 2017
Analysis of anti-tumour necrosis factor-induced skin lesions reveals strong T helper 1 activation with some distinct immunological characteristicsE Stoffel, H Maier, E Riedl, et al.
Clinical Immunology and Immunopathology|December 1, 1989
Interleukin 1-induced pathophysiology: induction of cytokines, development of histopathologic changes, and immunopharmacologic interventionL D Butler, N K Layman, R L Cain, et al.
The British Journal of Dermatology|June 5, 2015
Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trialK Papp, D Thaçi, K Reich, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Journal of Neuroimmunology|September 1, 1989
Neuroendocrine regulation of in vivo cytokine production and effects: I. In vivo regulatory networks involving the neuroendocrine system, interleukin-1 and tumor necrosis factor-alphaL D Butler, N K Layman, P E Riedl, et al.
American Journal of Veterinary Research|May 26, 2017
Evaluation of the effects of a 4.7-mg deslorelin acetate implant on egg laying in cockatiels (Nymphicus hollandicus)Noémie M Summa, David Sanchez-Migallon Guzman, Emma L Wils-Plotz, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 11, 2020
Ixekizumab improves secondary lesional signs, pain and sexual health in patients with moderate-to-severe genital psoriasisJ F Merola, P-D Ghislain, J N Dauendorffer, et al.
Immunopharmacology and Immunotoxicology|January 1, 1989
Interleukin-2 induced systemic toxicity: induction of mediators and immunopharmacologic interventionL D Butler, K M Mohler, N K Layman, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 1, 2022
An integrated analysis of herpes virus infections from eight randomized clinical studies of baricitinib in adults with moderate-to-severe atopic dermatitisT Werfel, A D Irvine, C Bangert, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 6, 2023
Speed of clinical improvement in the real-world setting from patient-reported Psoriasis Symptoms and Signs Diary: Secondary outcomes from the Psoriasis Study of Health Outcomes through 12 weeksA Reich, A Pinter, J-T Maul, et al.
The Journal of Dermatological Treatment|September 22, 2021
Pregnancy outcomes in patients with psoriasis, psoriatic arthritis, or axial spondyloarthritis receiving ixekizumabA Egeberg, L Iversen, A B Kimball, et al.
The British Journal of Dermatology|November 17, 2017
Analysis of anti-tumour necrosis factor-induced skin lesions reveals strong T helper 1 activation with some distinct immunological characteristicsE Stoffel, H Maier, E Riedl, et al.
Clinical Immunology and Immunopathology|December 1, 1989
Interleukin 1-induced pathophysiology: induction of cytokines, development of histopathologic changes, and immunopharmacologic interventionL D Butler, N K Layman, R L Cain, et al.
The British Journal of Dermatology|June 5, 2015
Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trialK Papp, D Thaçi, K Reich, et al.
Pageof 5